DS

Dhillon Shah

Active Director Director DIN 11116841
DIN 11116841 First appointment May 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since May 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Dhillon Shah

Data last updated:

Dhillon Shah is a Director at Euro Biogenics Private Limited (since 2025) and Director at Bharat Drugs & Pharmaceuticals Private Limited (since 2025). The companies operate in Pharma.

DIN 11116841
Primary Designation Director
Industry Pharma
First Appointment 20 May 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Euro Biogenics Private Limited U46497WB2025PTC280106
Director05 Jun 20252025Active
Director20 May 20252025Active

Board colleagues of Dhillon Shah

Directorship timeline

Open interactive timeline →
Euro Biogenics Private Limited
Bharat Drugs & Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Dhillon Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dhillon Shah

Dhillon Shah currently holds 2 directorships: Euro Biogenics Private Limited (Director, since 05 Jun 2025); Bharat Drugs & Pharmaceuticals Private Limited (Director, since 20 May 2025).

Dhillon Shah was first appointed on 20 May 2025 as Director at Bharat Drugs & Pharmaceuticals Private Limited.

The current boards of Dhillon Shah's companies include Anil Kumar Shah (Euro Biogenics Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available